28 results about "CXCL13" patented technology

Provided herein are methods and immune biomarkers that identify progression and treatment options for multiple sclerosis (MS). Also provided are materials and methods for the prognosis, staging, and monitoring of MS in a sample and include methods of determining a subject as being at risk of developing MS. The methods include detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3 in cerebrospinal fluid (CSF) in the subject; and administering a pharmaceutically effective amount of a treatment (e.g., tolebrutinib and potentially one or more additional therapies, such as an anti-CD20 therapy) to the subject.

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, P13, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM 23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.

A method of stabilizing a chemokine protein with a C-X-C or a C-C structural motif such as CXCL13 and CCL21 is provided. The method comprises the step of introducing the chemokine proteins into a solution comprising a buffer a non- ionic or amphoteric surfactant; and an aqueous chaotropic agent. A method of detecting a chemokine protein with a C-X-C or a C-C structural motif such as CXCL13 and CCL21 conjugated to antibodies thereto labelled with a fluorescent label in a solution is also provided. The method comprises the following steps: providing a test substrate comprising an elongate nitro cellulose membrane.

Provided herein are methods for manufacturing of tumor reactive T cells that includes ex vivo enrichment of, and expansion of, cells secreting chemokine (C-X-C motif) ligand 13 (CXCL13); cells surface positive for C-X-C chemokine receptor type 5 (CXCR5); and / or one or more of CD39, PD-1 and TIGIT. Also provided are populations of T cells produced by methods described herein and pharmaceutical compositions thereof.

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.

The invention provides a system and a method for detecting applicability of lung cancer immunotherapy. The invention discloses the expression ratio of ARG1 to CXCL13 or the expression ratio of CXCL13 to ARG1 for the first time, and the expression ratio can be used for predicting the applicability of immunotherapy of middle and late stage or advanced stage lung cancer, and has ideal sensitivity. On the basis, the invention also provides a system and a method for detecting the applicability of lung cancer immunotherapy. The invention provides a new scheme for diagnosis of clinical lung cancer immunotherapy applicability.

Provided herein are methods of making tumor reactive peripheral blood lymphocytes (trPBLs) using PBMCs obtained from a patient. The method comprises enriching trPBLs from PBMCs using markers that are expressed or secreted by the trPBLs, such as 4- IBB, CD103, CXCL13, IFN-y, CXCR6, CD200, HLA-DR, CD69, PD-1, CD39, CD38, CD49a, etc. Further provided are use of the trPBLs or pharmaceutical compositions thereof for the treatment of cancers.

The invention discloses an application of a DUF3109 protein in preparation of an antitumor drug. The DUF3109 protein is a bacteroides ovatus DUF3109 protein. The DUF3109 protein can promote the formation of a three-level lymph structure in a tumor by regulating CXCL13 secreted by CD4 + T cells, so that the progress of liver cancer is inhibited. In a specific embodiment, the DUF3109 protein shows that the DUF3109 protein has a remarkable inhibition effect on liver in-situ tumors and remarkably promotes CD4 < + > T lymphocytes and Jurkat cells to secrete CXCL13. According to the technical scheme, the application of the DUF3109 protein is expanded, a potential innovative solution is provided for tumor treatment, and a new research direction is provided for development of anti-tumor drugs.

The invention belongs to the technical field of tumor treatment drug research, and particularly relates to application of a neutralizing antibody of CXCL13 in preparation of a drug for improving radiation resistance. Experiments prove that the neutralizing antibody of CXCL13 improves radiation resistance of tumor patients by reducing immunosuppressive mononuclear cells induced by radiotherapy.

The present invention discloses a biomarker combination for predicting the applicability of immunotherapy for gastric cancer and its application. The biomarker combination includes the following proteins: CD160, CXCL13, and CD8. For the first time, the present invention reveals the immune cell characteristics of clinical samples of gastric cancer (GC) by using multiplex immunofluorescence technology combined with image data statistical analysis, and publicly describes the relationship between intratumoral infiltrating CD160<supgt;+< / supgt;CXCL13<supgt;+< / supgt;CD8<supgt;+< / supgt; T cells and the therapeutic efficacy of PD-1 inhibitor treatment. The design of the present invention is rigorous and has strong feasibility, providing new ideas and directions for the application of immunotherapy drugs for advanced gastric cancer, and having great clinical application value.

E. coli Nissle 1917 (EcN) engineered to express human chemokine CXCL13 (EcNhCXCL13) for intravesical delivery to treat muscle-invasive bladder cancer and similar disorders.

The invention provides application of a CXC chemokine ligand 13 as a vascular calcification diagnosis marker, and belongs to the technical field of medicines. The high expression of the CXCL13 prompts the high risk of vascular calcification, and the reagent for detecting the expression level of the CXC chemotactic factor ligand 13 can be used for preparing a vascular calcification early-warning reagent or early-warning kit. The invention studies the effect and molecular mechanism of CXCL13 in macrophages and vascular smooth muscle cells for regulating and controlling vascular calcification, provides an early intervention target for vascular calcification, and has great significance for early diagnosis and prevention of vascular calcification.

The invention relates to an application of a CXCL13 + CD8 + T cell subset in preparation of a product for predicting prognosis of a melanoma patient, and the CXCL13 + CD8 + T cell subset is used as an analysis target to prepare a reagent for analyzing immune cell functions. Wherein the CXCL13 < + > CD8 < + > T cell subset refers to a CD8 < + > T cell subset capable of releasing a CXCL13 signal. Compared with the prior art, the research shows that by analyzing the expression level of effector molecules and immune checkpoint molecules in a tumor microenvironment and the density of a three-level lymph structure, the prognosis of a tumor patient can be more accurately predicted, and the reactivity of tumors to immunotherapy can be predicted; at present, a report for reflecting immune characteristics of melanoma by using the CXCL13 + CD8 + T cell subset as a biomarker is not found. The infiltration level of CXCL13 + CD8 + T cells in tumor tissues is quantitatively evaluated through flow cytometry, and more accurate and sensitive indexes are provided for prognosis evaluation of melanoma and liver cancer patients.

The invention provides an anti-human CXCL13 rabbit monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of immune globulin, the anti-human CXCL13 rabbit monoclonal antibody can be specifically combined with CXCL13 protein, the specificity and sensitivity of immunodetection are remarkably improved, the anti-human CXCL13 rabbit monoclonal antibody is suitable for preparing an immunohistochemical detection kit, and the anti-human CXCL13 rabbit monoclonal antibody can be used for preparing immunohistochemical detection products. CXCL13 protein expression can be accurately detected, and a reliable tool is provided for diagnosis of diseases such as vascular immune maternal T cell lymphoma and peripheral T cell lymphoma.

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM 23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.

The application discloses application of DUF3109 protein in preparation of an antitumor drug, wherein the DUF3109 protein is Bacteroides ovatus DUF3109 protein. The DUF3109 protein can inhibit the progression of liver cancer by regulating CD4+ T cell secretion of CXCL13 and promoting the formation of intratumoral tertiary lymphoid structures. In specific embodiments, the DUF3109 protein exhibits significant inhibitory effect on liver orthotopic tumors and significant promotion of CD4+ T lymphocyte and Jurkat cell secretion of CXCL13. The technical scheme of the application not only expands the use of the DUF3109 protein, but also provides a potential innovative solution for tumor treatment and a new research direction for development of an antitumor drug.

The invention belongs to the technical field of cell biology, and particularly discloses a method for differentiating CXCL13OE stem cells into T cells, which comprises the following steps: (i) culturing iPSC; (ii) carrying out lentivirus transfection to construct a CXCL13 overexpression iPSC; (iii) the CXCL13OE-iPSC differentiates the CXCL13 < + > CD34 < + > hematopoietic progenitor cells; (iv) differentiating the T progenitor cells from the CXCL13 + CD34 + hematopoietic progenitor cells; (v) differentiating the CXCL13 + T progenitor cell into a double positive cell CXCL13 + DP-T cell; and (vi) differentiating a CD8 + CXCL13 + Texp T cell subset by using the double positive CXCL13 + DP-T cells. The CD8 + CXCL13 + Texp T cell subset is further prepared on the basis of constructing CXCL13OE stem cells from the iPSC level, so that on one hand, the problem of low expression of CXCL13 by T cells differentiated by the iPSC is solved, and on the other hand, the difficulty that CXCL13 overexpression and screening cannot be carried out on the CD8 + T cells is solved. Therefore, the complementation of high-targeting and lethality CD8 + T cells lacking in the body of a tumor patient is facilitated.

Provided herein are methods and immune biomarkers for identifying multiple sclerosis (MS) progression and treatment options. Materials and methods for prognosing, staging, and monitoring MS in a sample are also provided, including methods for determining a subject as at risk for developing MS. The methods include detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3, in the cerebrospinal fluid (CSF) of a subject, and administering a pharmaceutically effective amount of a therapy (e.g., trebrutinib and potentially one or more additional therapies, e.g., an anti-CD20 therapy) to the subject.

This invention provides an anti-human CXCL13 rabbit monoclonal antibody, its preparation method, and its application, belonging to the field of immunoglobulin technology. This invention provides an anti-human CXCL13 rabbit monoclonal antibody that can specifically bind to the CXCL13 protein, significantly improving the specificity and sensitivity of immunoassay. It is suitable for preparing immunohistochemical detection kits and can accurately detect CXCL13 protein expression, providing a reliable tool for the diagnosis of diseases such as angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.

Provided herein are methods and immune biomarkers for identifying progression and therapeutic selection of multiple sclerosis (MS). Also provided are materials and methods for prognosis, staging, and monitoring of MS in a sample, and including methods of determining that a subject is at risk of developing MS. The method comprises detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3, in the cerebrospinal fluid (CSF) of the subject; and administering to the subject a pharmaceutically effective amount of a treatment (e.g., tobutinib and potentially one or more additional therapies, such as an anti-CD20 therapy).

The invention relates to a CXCL13mRNA drug and an application of the CXCL13mRNA drug in tumor treatment. The present invention provides a lipid particle comprising an ionizable lipid, a phospholipid, a cholesterol, a PEG-lipid, and a CXCL13 mRNA encapsulated within the lipid particle. The invention also provides a pharmaceutical composition comprising the lipid particle and application thereof. The medicine containing CXCL13mRNA provided by the invention is particularly suitable for treating tumors including lung cancer, colorectal cancer, breast cancer, liver cancer, pancreatic cancer, head and neck cancer, brain glioma, melanoma and the like.

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.

Disclosed is a method for modifying a fibroblast. The method comprises the following steps: collecting peripheral blood from a healthy person, extracting peripheral blood mononuclear cells from the peripheral blood in vitro by using a lymphocyte separation medium, and sorting and purifying B cells by using immunomagnetic beads; and constructing human CXCL13, TNFSF13B and VCAM1 overexpression plasmids by using molecular cloning technology, and infecting MRC-5 with a lentivirus to obtain an MRC-5 fibroblast simultaneously overexpressing CXCL13, TNFSF13B and VCAM1. Further provided is a modified fibroblast obtained on the basis of the method. Further provided is the use of the modified fibroblast in terms of inducing B-cell chemotaxis, inducing B-cell adhesion and promoting antibody secretion in B cells. The modified fibroblast can be used in the chemotaxis and adhesion of B cells, promotes antibody secretion in B cells, and has good clinical application value.

Disclosed herein are methods and compositions for treating cancer by eliciting an immune response by administering dendritic cells expressing heterologous proteins. In some embodiments, a dendritic cell comprises one or more heterologous nucleic acid molecules encoding for CD40L and CXCL13. In some embodiments, the dendritic cell further comprises a heterologous nucleic acid molecule encoding for CD93. In yet additional embodiments, the dendritic cells expressing heterologous proteins are activated.

This invention discloses a novel CD8 + T cells and CD4 + T cell subsets. The CD8... + T cell subsets include: subsets characteristically expressing GZMK and PDCD1; subsets characteristically expressing GZMK, GPR183, IL7R, and ZNF683; subsets characteristically expressing GZMK and CXCL13; subsets characteristically expressing GZMK and ZNF683; and subsets expressing at least one of the following KIR genes: KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2, and KIR3DL3. The CD4+... + T cell subsets include: subsets that characteristically express FOXP3, TNFRSF9, and CTLA4; and subsets that characteristically express FOXP3 and BACH1.

Disclosed herein are methods and compositions for treating cancer by eliciting an immune response by administering dendritic cells expressing heterologous proteins. In some embodiments, a dendritic cell comprises one or more heterologous nucleic acid molecules encoding for CD40L and CXCL13. In some embodiments, the dendritic cell further comprises a heterologous nucleic acid molecule encoding for CD93. In yet additional embodiments, the dendritic cells expressing heterologous proteins are activated.

The present invention relates to a method of identifying a T-cell reactive to cells presenting a T-cell activating antigen (cancer-reactive T-cell), comprising (a) determining expression of at least one of CCL4. CCL4L2. CCL3. CCL3L1, and CXCL13 in T-cells from a sample of a subject: and (b) identifying a cancer-reactive T-cell based on the determination of step (a). The present invention also relates to a method of identifying a TCR binding to a cancer cell of a subject. said method comprising (A) identifying a cancer reactive T-cell according to the afore-said method (B) providing the amino acid sequences of at least the complementarity determining regions (CDRs) of the TCR of the cancer-reactive T-cell identified in step (A): and. hereby. (C) identifying a TCR binding to a cancer cell. The present invention further relates to further methods and cancer-reactive T-cells related thereto.

The present disclosure relates, in part, to the discovery that CD4+ T cells characterized by certain markers are over-represented in solid tumors. Markers include, for example, CD200, CXCL13, and PD-1, as well as combinations of these, and other markers. The markers can identify CD4+ T cells having certain phenotypes. Identifying such cells enables a variety of therapeutic and prognostic applications. Such CD4+ T cells will typically include those specific for a tumor neoantigen or antigen, and may be enriched for and / or expanded and used in a T cell therapy. TCRs from such CD4+ T cells may be used in therapy (e.g., comprising T cells recombinantly expressing such a TCR or an engineered TCR or binding domain derived therefrom). The relative presence or absence of such CD4+ T cells in a tumor sample can provide information regarding the immune state of the subject and the likely prognosis of disease.